Goldman Sachs
ASMB icon

Goldman Sachs’s Assembly Biosciences ASMB Stock Holding History

Goldman Sachs’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,083
Closed -$483K – 5221
2018
Q3 		$483K Hold
1,083
– – ﹤0.01% 4441
2018
Q2 		$510K Buy
+1,083
New +$573K ﹤0.01% 4495

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Goldman Sachs's ASMB Position: Q2 2026 in Review

Goldman Sachs increased its Assembly Biosciences (ASMB) stake by 281% in Q2 2026, buying an estimated $2.77M and bringing the position to 137,833 shares worth $3.79M. The position accounts for ﹤0.01% of the portfolio, ranked #4138.

Goldman Sachs first reported a position in ASMB in Q1 2014 and has held it in 37 quarters since. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Goldman Sachs held 137,833 shares of Assembly Biosciences worth $3.79M as of Q2 2026.
  • Goldman Sachs bought 101,628 Assembly Biosciences shares in Q2 2026, an estimated $2.77M.
  • Assembly Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4138 holding.
  • Goldman Sachs first reported a position in Assembly Biosciences in Q1 2014 and has held it in 37 quarters since.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.